Nuvectis Pharma, Inc.
NVCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875558
In the last 90 days, Nuvectis Pharma, Inc. insiders filed 2 open-market purchases and 0 sales; 82 institutions reported holding it in 13F filings for Q2 2026, worth $190.8M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $1.17M in total
- 2
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +22 vs. previous quarter
- 82
- 13F valueReported value at the end of Q2 2026
- $190.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding NVCT, Q2 2026
No superinvestor reported holding NVCT at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Nuvectis Pharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 (view filing)1:41 PM ET | Jun 30 | 1 day | Mosseri Marlio Charles10% Owner | PPurchase | +50.0K | $18.32 | +$916.0K | +1.6%3.19M after | |
| Jul 1, 2026 (view filing)1:39 PM ET | Jun 30 | 1 day | Bentsur RonChairman & CEO | PPurchase | +12.5K | $20.00 | +$250.0K | +0.3%3.69M after | |
| Nov 6, 2025 (view filing) | Nov 5 | 1 day | Bentsur RonChairman & CEO | PPurchase | +5.00K | $5.72 | +$28.6K | +0.1%3.53M after | |
| Nov 6, 2025 (view filing) | Nov 5 | 1 day | Sanchez JuanDirector | PPurchase | +13.0K | $5.79 | +$75.3K | +20.0%78.2K after | |
| Nov 6, 2025 (view filing) | Nov 5 | 1 day | Kaplan Matthew L.Director | PPurchase | +11.0K | $5.84 | +$64.2K | +9.7%124.8K after | |
| Oct 29, 2025 (view filing) | Oct 23-27 | 6 daysLate | Mosseri Marlio Charles10% Owner | PPurchase | +154.8K | $6.18 | +$957.1K | +5.2%3.14M after | 3 lots |
| Jun 24, 2025 (view filing) | Jun 20 | 4 days | Mosseri Marlio Charles10% Owner | PPurchase | +5.60K | $7.99 | +$44.8K | +0.2%2.98M after | |
| Jun 20, 2025 (view filing) | Jun 17-18 | 3 days | Mosseri Marlio Charles10% Owner | PPurchase | +33.4K | $8.06 | +$269.5K | +1.1%2.98M after | 2 lots |
| May 13, 2025 (view filing) | May 12 | 1 day | Mosseri Marlio Charles10% Owner | PPurchase | +21.2K | $8.11 | +$171.7K | +0.7%2.94M after | |
| May 12, 2025 (view filing) | May 8-9 | 4 days | Mosseri Marlio Charles10% Owner | PPurchase | +27.7K | $8.94 | +$247.3K | +1.0%2.94M after | Amended6 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Nuvectis Pharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 1,550,000 | $28.5M | 1.29% | +1,550,000 | New |
| BlackRock, Inc. | 1,001,285 | $18.4M | 0.00% | +236,844+31.0% | Added |
| Perceptive Advisors LLC | 1,000,000 | $18.4M | 0.29% | +1,000,000 | New |
| Soleus Capital Management, L.P. | 1,000,000 | $18.4M | 0.63% | +1,000,000 | New |
| Vanguard Capital Management LLC | 872,482 | $16.0M | 0.00% | +212,603+32.2% | Added |
| Iridian Asset Management LLC | 777,078 | $14.3M | 4.91% | +125,321+19.2% | Added |
| Geode Capital Management, LLC | 432,273 | $7.95M | 0.00% | +48,168+12.5% | Added |
| Occam Crest Management LP | 357,147 | $7.39M | 4.08% | −50,000−12.3% | Reduced |
| Sphera Funds Management Ltd. | 382,945 | $7.04M | 1.01% | +382,945 | New |
| Baldwin Brothers Inc | 382,015 | $7.03M | 0.46% | +3,390+0.9% | Added |